Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Family Medicine›Condition·Updated Jul 11, 2026·v1

Tobacco Cessation Interventions

Tobacco cessation interventions are highly effective, with combined pharmacotherapy and behavioral support yielding the highest quit rates. Universal screening, brief intervention, and proactive outreach are essential, especially in high-risk populations such as those with mental illness, low SES, and pregnancy.

High Evidence77 references·8,742 words·35 min read·v1
tobacco cessationsmoking cessationnicotine dependencevareniclinebupropionnicotine replacement therapybehavioral counselingpreventive medicineUSPSTF grade A

Quick Reference

RxDrug of choiceVarenicline (1 mg BID for 12 weeks) or combination NRT (patch plus short-acting form like gum or lozenge).
AltAlternativesBupropion SR (150 mg BID), NRT monotherapy (patch, gum, lozenge, inhaler, nasal spray).
⊘AvoidE-cigarettes not recommended (insufficient evidence); pharmacotherapy in pregnancy insufficient evidence; avoid bupropion in seizure disorders.
DxTest of choiceFagerström Test for Nicotine Dependence (FTND), 6-item questionnaire, score 0-10.
ScKey scoreFTND ≥6 indicates high dependence, requiring combination pharmacotherapy.
→When to referMultiple failed quit attempts, serious mental illness, pregnancy, need for intensive behavioral counseling or tobacco treatment specialist.
Screen all, advise all, offer pharmacotherapy + behavioral support, and arrange follow-up.
Tobacco use is the leading preventable cause of death, and cessation interventions are among the most effective clinical preventive services. The USPSTF recommends universal screening and intervention for all adults and pregnant women. Combined pharmacotherapy and behavioral counseling yields the highest quit rates, with number needed to treat as low as 6 in high-risk populations. Proactive outreach, hospital-initiated programs, and sustained follow-up significantly improve long-term abstinence.

Overview and Recommendations

Background

  • •Tobacco use is the leading preventable cause of death globally, responsible for over 480,000 US deaths annually. Cessation interventions are among the most cost-effective clinical preventive services, with the USPSTF issuing a Grade A recommendation for universal screening and intervention.
  • •Nicotine dependence is driven by dopamine release in the mesolimbic pathway, reinforced by psychosocial factors such as stress coping and social bonding. This creates a self-reinforcing cycle that heightens cravings for other substances and complicates sustained abstinence.
  • •The three main intervention categories are behavioral counseling (individual, group, telephone quitline), pharmacotherapy (nicotine replacement therapy [NRT], varenicline, bupropion SR), and their combination. Combined therapy yields the highest abstinence rates, with a pooled relative risk of 1.83 compared to minimal support.
  • •Certain populations bear a disproportionate burden: people with HIV are 2-3 times more likely to smoke, individuals with schizophrenia have a 10-year shorter life expectancy partly due to smoking, and low-SES smokers have lower quit rates. Tailored interventions are critical.
  • •Evidence-based interventions include the 5A's framework (Ask, Advise, Assess, Assist, Arrange) and the Ottawa Model, which integrates hospital-initiated counseling, NRT, and telephone follow-up to reduce readmissions and mortality.

Evaluation

  • •Suspect tobacco use disorder in any patient using any tobacco product. Screen universally at every clinical encounter with a single question: "Do you use any tobacco products?"
  • •Ask about the type of tobacco (cigarettes, smokeless, e-cigarettes, hookah, cigars), quantity (cigarettes per day), duration of use, and time to first cigarette after waking, the single strongest indicator of nicotine dependence.
  • •Inquire about past quit attempts: what methods were tried, why they failed, and how long abstinence lasted. Withdrawal symptoms (irritability, craving, anxiety, difficulty concentrating) typically begin within 24 hours of cessation.
  • •Examine for physical signs of chronic tobacco use: tobacco odor, nicotine staining of fingers, chronic cough, and oral leukoplakia (especially with smokeless tobacco).
  • •For patients with comorbid HIV, tuberculosis, or psychotic disorders, recognize that tobacco use is more prevalent and cessation is especially urgent due to higher mortality.
  • •The gold-standard diagnostic assessment is the clinical interview using DSM-5 criteria for tobacco use disorder. For rapid quantification, use the Fagerström Test for Nicotine Dependence (FTND), a 6-item questionnaire scored 0-10; a score ≥6 indicates high dependence.
  • •An alternative rapid screen is the Heaviness of Smoking Index (HSI), using time to first cigarette and cigarettes per day; a score ≥4 indicates high dependence.
  • •Assess readiness to quit using the Readiness to Change Ruler (0-10) or the Stages of Change model. A score of ≥7 suggests the patient is ready to make a quit attempt within 30 days.
  • •Biochemical verification (exhaled carbon monoxide <10 ppm or urine/serum cotinine) is not required for routine diagnosis but is useful in research, pregnancy, or when misreporting is suspected.
  • •Apply the 5A's framework systematically: Ask about use, Advise to quit, Assess willingness, Assist with pharmacotherapy and counseling, and Arrange follow-up. National data show that 88% of smokers are asked but only 18% have follow-up arranged, the largest gap.
  • •For patients with high dependence (FTND ≥6) or comorbid mental illness, plan for combination pharmacotherapy (e.g., NRT patch plus gum) and referral to intensive behavioral support.

Management

  • •At every acute care encounter, deliver a brief intervention (≤3 minutes): advise the patient to quit, assess readiness, and offer assistance. Even 30 seconds of advice increases the likelihood of a quit attempt (NNT=6).
  • •For nonpregnant adults ready to quit, initiate first-line pharmacotherapy: varenicline (start 0.5 mg daily for 3 days, then 0.5 mg BID for 4 days, then 1 mg BID for 12 weeks); bupropion SR (150 mg daily for 3 days, then 150 mg BID for 7-12 weeks); or NRT (patch, gum, lozenge, inhaler, or nasal spray per label).
  • •For patients with high nicotine dependence (FTND ≥6), use combination NRT, a transdermal patch (e.g., 21 mg/24 hours) plus a short-acting form (gum 2-4 mg hourly or lozenge), to improve quit rates.
  • •Combine pharmacotherapy with behavioral counseling: the pooled relative risk for combined therapy is 1.83 compared to minimal support, significantly better than either alone.
  • •For low-SES smokers, implement proactive outreach with telephone counseling, free NRT for 6 weeks, and community referrals; this achieves a 17.8% quit rate versus 8.1% (NNT=10).
  • •For patients with schizophrenia or serious mental illness, use a personalized intervention package (counseling plus pharmacotherapy) to achieve 28% abstinence at 6 months (NNT=6).
  • •In adolescents (<20 years), group counseling is effective (RR 1.35); pharmacotherapy and individual counseling have insufficient evidence and should not be used as first-line.
  • •In pregnant women, behavioral counseling is the first-line intervention; do not initiate pharmacotherapy due to insufficient evidence of benefit and unknown harms. Refer to specialized prenatal cessation support.
  • •For perioperative patients, offer a cessation intervention at least 4 weeks before surgery to reduce postoperative complications; NNT=7 for abstinence at the time of surgery.
  • •Extend pharmacotherapy beyond 12 weeks for patients at high risk of relapse; the USPSTF supports use up to 6 months.
  • •Refer all patients to a state quitline (1-800-QUIT-NOW) for ongoing telephone counseling; this is accepted by >90% of patients and increases abstinence.
  • •The Ottawa Model (hospital-initiated counseling, NRT, and telephone follow-up) reduces all-cause 30-day readmission (ARR 6.1%, NNT=17) and 1-year mortality (ARR 6.0%, NNT=17).
  • •What NOT to do: do not rely solely on written materials; do not assume patients are uninterested; do not recommend e-cigarettes for cessation (insufficient evidence).
  • •Monitor for adverse effects of pharmacotherapy: varenicline may cause nausea, insomnia, and rare neuropsychiatric events; bupropion may lower seizure threshold; NRT may cause local skin reactions or oral irritation.
  • •For patients with multiple failed quit attempts or co-occurring substance use disorders, refer to a tobacco treatment specialist or addiction medicine program.

Board Review — High Yield

  • •Fagerström Test for Nicotine Dependence (FTND), A 6-item score (0-10); ≥6 indicates high dependence requiring combination pharmacotherapy.
  • •The 5A's, Ask, Advise, Assess, Assist, Arrange; only 18% of smokers receive the Arrange step.
  • •Varenicline, Pooled RR 2.24 for abstinence at 6 months vs placebo; start 0.5 mg daily, titrate to 1 mg BID.
  • •Proactive outreach, Telephone counseling + free NRT + community referrals yields NNT=10 in low-SES smokers.
  • •Perioperative cessation, NNT=7 for abstinence at surgery, reducing postoperative complications.
  • •Ottawa Model, Hospital-initiated counseling + NRT + follow-up reduces 30-day readmission (NNT=17) and 1-year mortality (NNT=17).
  • •Pregnancy, Behavioral counseling is first-line; pharmacotherapy has insufficient evidence.
  • •Adolescents, Group counseling effective (RR 1.35); pharmacotherapy not proven.
  • •Schizophrenia, Personalized intervention package achieves 28% abstinence at 6 months (NNT=6).
  • •Combined therapy, Pharmacotherapy + behavioral support: RR 1.83 vs minimal support.

Deep Dive — Evidence Details

References

  1. [1]

    Carr AB, Ebbert J. “Interventions for tobacco cessation in the dental setting.” The Cochrane database of systematic reviews (2012). PMID: 22696348 ↗

    L1SR_OBSCited in: Definition, Classification and Nomenclature, Long-term and Definitive Management, Prognosis and Natural History
  2. [2]

    Holliday R, Hong B, McColl E et al.. “Interventions for tobacco cessation delivered by dental professionals.” The Cochrane database of systematic reviews (2021). PMID: 33605440 ↗

    L1SR_OBSCited in: Definition, Classification and Nomenclature, Long-term and Definitive Management, Prognosis and Natural History
  3. [3]

    Grimshaw GM, Stanton A. “Tobacco cessation interventions for young people.” The Cochrane database of systematic reviews (2006). PMID: 17054164 ↗

    L1SR_OBSCited in: Definition, Classification and Nomenclature, Epidemiology, Etiology and Risk Factors, Long-term and Definitive Management, Prognosis and Natural History, Prevention, Screening and Health Maintenance
  4. [4]

    Apollonio D, Philipps R, Bero L. “Interventions for tobacco use cessation in people in treatment for or recovery from substance use disorders.” The Cochrane database of systematic reviews (2016). PMID: 27878808 ↗

    L1SR_OBSCited in: Definition, Classification and Nomenclature, Diagnosis and Workup, Long-term and Definitive Management
  5. [5]

    Vijayaraghavan M, Elser H, Frazer K et al.. “Interventions to reduce tobacco use in people experiencing homelessness.” The Cochrane database of systematic reviews (2020). PMID: 33284989 ↗

    L1SR_OBSCited in: Definition, Classification and Nomenclature, Severity, Staging and Risk Stratification
  6. [6]

    Shen X, Bachyrycz A, Anderson JR et al.. “Quitting patterns and predictors of success among participants in a tobacco cessation program provided by pharmacists in New Mexico.” Journal of managed care & specialty pharmacy (2014). PMID: 24856596 ↗

    L4OTHERCited in: Definition, Classification and Nomenclature
  7. [7]

    Chiseya LS, Myers B. “"Cigarettes led me back to smoking tik": lived experience perspectives on tobacco use during substance use treatment and recovery in South Africa.” Addiction science & clinical practice (2026). PMID: 41821057 ↗

    L5OTHERCited in: Pathophysiology and Mechanism
  8. [8]

    Martinez Leal I, Taing M, Correa-Fernández V et al.. “Addressing Smoking Cessation among Women in Substance Use Treatment: A Qualitative Approach to Guiding Tailored Interventions.” International journal of environmental research and public health (2021). PMID: 34072064 ↗

    L5OTHERCited in: Pathophysiology and Mechanism
  9. [9]

    Shelley D, Armstrong-Hough M, Nguyen T et al.. “Effectiveness of behavioural tobacco cessation interventions with and without pharmacotherapy among people living with HIV in Viet Nam: a three-arm pragmatic randomised controlled trial.” The Lancet. Global health (2026). PMID: 41713442 ↗

    L1RCTCited in: Epidemiology, Etiology and Risk Factors, Long-term and Definitive Management, Prognosis and Natural History
  10. [10]

    Rajalu BM, Jayarajan D, Muliyala KP et al.. “Effectiveness of personalized tobacco cessation intervention package among patients with schizophrenia and related psychotic disorders - A two-group experimental study.” Asian journal of psychiatry (2023). PMID: 36652840 ↗

    L1RCTCited in: Epidemiology, Etiology and Risk Factors, History and Evolution of Treatment, Prognosis and Natural History
  11. [11]

    Awaisu A, Nik Mohamed MH, Mohamad Noordin N et al.. “The SCIDOTS Project: evidence of benefits of an integrated tobacco cessation intervention in tuberculosis care on treatment outcomes.” Substance abuse treatment, prevention, and policy (2011). PMID: 21943384 ↗

    L2RCTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup
  12. [12]

    Stanton A, Grimshaw G. “Tobacco cessation interventions for young people.” The Cochrane database of systematic reviews (2013). PMID: 23975659 ↗

    L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Long-term and Definitive Management, Prognosis and Natural History, Prevention, Screening and Health Maintenance
  13. [13]

    Wipfli H, Arinaitwe J, Goma F et al.. “A phone-based tobacco use cessation program for people living with HIV in Uganda and Zambia: study protocol for a randomized controlled trial.” Addiction science & clinical practice (2024). PMID: 38243301 ↗

    L5TRIAL_NONRANDOMCited in: Epidemiology, Etiology and Risk Factors, Long-term and Definitive Management
  14. [14]

    Rasmussen M, Larsson M, Gilljam H et al.. “Effectiveness of tobacco cessation interventions for different groups of tobacco users in Sweden: a study protocol for a national prospective cohort study.” BMJ open (2022). PMID: 35078840 ↗

    L5TRIAL_NONRANDOMCited in: Epidemiology, Etiology and Risk Factors, Long-term and Definitive Management
  15. [15]

    Mahabee-Gittens EM, Gordon J. “Acceptability of tobacco cessation interventions in the pediatric emergency department.” Pediatric emergency care (2008). PMID: 18431218 ↗

    L4RCTCited in: Epidemiology, Etiology and Risk Factors, Acute Management
  16. [16]

    Heshmati J, Abraham A, Miles J et al.. “Tobacco cessation strategies in military personnel: A meta-analysis of randomized trials.” Preventive medicine reports (2025). PMID: 41477657 ↗

    L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors
  17. [17]

    Rajan V, Muralikrishnan S, Nagappa B et al.. “Continued tobacco use beyond cancer diagnosis in India - A systematic review and meta-analysis.” Journal of cancer policy (2025). PMID: 40484231 ↗

    L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup, Prevention, Screening and Health Maintenance
  18. [18]

    Han B, Aung TW, Volkow ND et al.. “Tobacco Use, Nicotine Dependence, and Cessation Methods in US Adults With Psychosis.” JAMA network open (2023). PMID: 36976558 ↗

    L4OTHERCited in: Clinical Presentation, Diagnosis and Workup, Severity, Staging and Risk Stratification
  19. [19]

    Reed D, Danberry K. “Smokeless Tobacco Cessation in an Emergency Room in Rural West Virginia.” Frontiers in public health (2022). PMID: 35462820 ↗

    L4OTHERCited in: Clinical Presentation, Acute Management
  20. [20]

    Irwin KE, Steffens EB, Yoon Y et al.. “Lung Cancer Screening Eligibility, Risk Perceptions, and Clinician Delivery of Tobacco Cessation Among Patients With Schizophrenia.” Psychiatric services (Washington, D.C.) (2019). PMID: 31357921 ↗

    L4OTHERCited in: Clinical Presentation
  21. [21]

    Rodríguez-Esquivel D, Cooper TV, Blow J et al.. “Characteristics associated with smoking in a Hispanic sample.” Addictive behaviors (2009). PMID: 19394148 ↗

    L4OTHERCited in: Clinical Presentation, Complications
  22. [22]

    Wichman ML, Wall DM, Garcia Mota SS et al.. “Perspectives on Using Pharmacogenomics to Guide Tobacco Cessation: Survey Results From an American Indian Community.” Clinical and translational science (2025). PMID: 40078094 ↗

    L4OTHERCited in: Clinical Presentation
  23. [23]

    Rogova A, Reitzel LR, Lowenstein LM et al.. “Implementation of a hybrid lung health program for Northeast Texas: study protocol.” Implementation science communications (2026). PMID: 41709306 ↗

    L5OTHERCited in: Clinical Presentation
  24. [24]

    Thomas T, Pradeep Raj J, Pinheiro T et al.. “Effectiveness of tobacco cessation interventions and risk factors for tobacco-use relapse: A cohort study.” The National medical journal of India (2026). PMID: 42240507 ↗

    L4COHORTCited in: Clinical Presentation
  25. [25]

    Rigotti NA, Chang Y, Rosenfeld LC et al.. “Interactive Voice Response Calls to Promote Smoking Cessation after Hospital Discharge: Pooled Analysis of Two Randomized Clinical Trials.” Journal of general internal medicine (2017). PMID: 28616847 ↗

    L2RCTCited in: Diagnosis and Workup, Long-term and Definitive Management, History and Evolution of Treatment, Prevention, Screening and Health Maintenance
  26. [26]

    Elf JL, Lebina L, Motlhaoleng K et al.. “A randomized trial for combination nicotine replacement therapy for smoking cessation among people with HIV in a low-resourced setting.” AIDS (London, England) (2024). PMID: 39693492 ↗

    L1RCTCited in: Diagnosis and Workup, Long-term and Definitive Management, History and Evolution of Treatment, Prognosis and Natural History, Prevention, Screening and Health Maintenance
  27. [27]

    Carr AB, Ebbert JO. “Interventions for tobacco cessation in the dental setting.” The Cochrane database of systematic reviews (2006). PMID: 16437517 ↗

    L1SR_OBSCited in: Diagnosis and Workup, Long-term and Definitive Management
  28. [28]

    Petrelli F, Ghidini A, Rossitto M et al.. “An umbrella review of meta-analyses on smoking cessation and cancer survival: a brief report.” Lung cancer (Amsterdam, Netherlands) (2025). PMID: 41005236 ↗

    L5SR_OBSCited in: Diagnosis and Workup, Prevention, Screening and Health Maintenance
  29. [29]

    Carr AB, Ebbert JO. “Interventions for tobacco cessation in the dental setting. A systematic review.” Community dental health (2007). PMID: 17615820 ↗

    L1SR_OBSCited in: Diagnosis and Workup
  30. [30]

    Yu LQ, Amato MS, Papandonatos GD et al.. “Predicting Early Dropout in a Digital Tobacco Cessation Intervention: Replication and Extension Study.” Journal of medical Internet research (2024). PMID: 39602788 ↗

    L3OTHERCited in: Diagnosis and Workup
  31. [31]

    Thielking AM, Fitzmaurice KP, Sewpaul R et al.. “Tobacco smoking, smoking cessation and life expectancy among people with HIV on antiretroviral therapy in South Africa: a simulation modelling study.” Journal of the International AIDS Society (2024). PMID: 38924347 ↗

    L2OTHERCited in: Diagnosis and Workup
  32. [32]

    Crosland P, Scollo M, White SL et al.. “Cost-effectiveness and productivity impacts of call-back telephone counselling for smoking cessation.” Public health research & practice (2023). PMID: 37287193 ↗

    L2OTHERCited in: Diagnosis and Workup
  33. [33]

    Jeyashree K, Kathirvel S, Shewade HD et al.. “Smoking cessation interventions for pulmonary tuberculosis treatment outcomes.” The Cochrane database of systematic reviews (2016). PMID: 26777994 ↗

    L1SR_OBSCited in: Severity, Staging and Risk Stratification, Long-term and Definitive Management
  34. [34]

    Mullen KA, Garg A, Gagnon F et al.. “The INITIATE trial protocol: a randomized controlled trial testing the effectiveness of a "quit card" intervention on long-term abstinence among tobacco smokers presenting to the emergency department.” Trials (2021). PMID: 34688291 ↗

    L5TRIAL_NONRANDOMCited in: Severity, Staging and Risk Stratification, Acute Management
  35. [35]

    Qin A, Wang M, Qi Y et al.. “Is tobacco dependence a moderator of psychiatric symptom severity and caregiver abuse in rural families of patients with severe mental disorders?” Psychological medicine (2025). PMID: 41310965 ↗

    L4OTHERCited in: Severity, Staging and Risk Stratification
  36. [36]

    Beckodro CK, Conteh V, Nsitou B et al.. “Tobacco smoking and postpartum depression symptoms in the Pregnancy Risk Assessment and Monitoring System (PRAMS) study.” Journal of affective disorders (2025). PMID: 40288456 ↗

    L4OTHERCited in: Severity, Staging and Risk Stratification, Special Populations and Pregnancy
  37. [37]

    Ripley GH, Carlin VE, Deyo AG et al.. “Severity of Disability-Related Functional Difficulties and Tobacco Use Patterns in a National Sample of U.S. Veterans.” Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco (2026). PMID: 42372058 ↗

    L4OTHERCited in: Severity, Staging and Risk Stratification
  38. [38]

    Melzer AC, Feemster LC, Crothers K et al.. “Respiratory and Bronchitic Symptoms Predict Intention to Quit Smoking among Current Smokers with, and at Risk for, Chronic Obstructive Pulmonary Disease.” Annals of the American Thoracic Society (2016). PMID: 27268422 ↗

    L4OTHERCited in: Severity, Staging and Risk Stratification
  39. [39]

    Walters EL, Reibling ET, Wilber ST et al.. “Emergency department provider preferences related to clinical practice guidelines for tobacco cessation: a multicenter survey.” Academic emergency medicine : official journal of the Society for Academic Emergency Medicine (2014). PMID: 25112653 ↗

    L4GUIDELINECited in: Acute Management, Generalist Reasoning under Diagnostic Uncertainty, Point-of-Care Scores & Referral Thresholds
  40. [40]

    Christiansen BA, Brooks M, Keller PA et al.. “Closing tobacco-related disparities: Using community organizations to increase consumer demand.” American journal of preventive medicine (2010). PMID: 20176314 ↗

    L1RCTCited in: Acute Management
  41. [41]

    Plever S, Kisely SR, Bonevski B et al.. “Interventions for smoking cessation in inpatient psychiatry settings.” The Cochrane database of systematic reviews (2026). PMID: 42389948 ↗

    L1SR_OBSCited in: Acute Management, Long-term and Definitive Management
  42. [42]

    Pelletier JH, Strout TD, Baumann MR. “A systematic review of smoking cessation interventions in the emergency setting.” The American journal of emergency medicine (2014). PMID: 24768666 ↗

    L5SR_OBSCited in: Acute Management, Generalist Reasoning under Diagnostic Uncertainty, Point-of-Care Scores & Referral Thresholds
  43. [43]

    Russell AM, Colditz JB, Barry AE et al.. “Analyzing Twitter Chatter About Tobacco Use Within Intoxication-related Contexts of Alcohol Use: "Can Someone Tell Me Why Nicotine is So Fire When You're Drunk?".” Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco (2022). PMID: 34562100 ↗

    L5OTHERCited in: Acute Management
  44. [44]

    Mullen KA, Manuel DG, Hawken SJ et al.. “Effectiveness of a hospital-initiated smoking cessation programme: 2-year health and healthcare outcomes.” Tobacco control (2016). PMID: 27225016 ↗

    L2OTHERCited in: Acute Management
  45. [45]

    Krist AH, Davidson KW, Mangione CM et al.. “Interventions for Tobacco Smoking Cessation in Adults, Including Pregnant Persons: US Preventive Services Task Force Recommendation Statement.” JAMA (2021). PMID: 33464343 ↗

    L1GUIDELINECited in: Long-term and Definitive Management, History and Evolution of Treatment, Complications, Special Populations and Pregnancy
  46. [46]

    Patnode CD, Henderson JT, Coppola EL et al.. “Interventions for Tobacco Cessation in Adults, Including Pregnant Persons: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.” JAMA (2021). PMID: 33464342 ↗

    L1SR_OBSCited in: Long-term and Definitive Management, Special Populations and Pregnancy
  47. [47]

    Haas JS, Linder JA, Park ER et al.. “Proactive tobacco cessation outreach to smokers of low socioeconomic status: a randomized clinical trial.” JAMA internal medicine (2015). PMID: 25506771 ↗

    L1RCTCited in: Long-term and Definitive Management, History and Evolution of Treatment, Prognosis and Natural History, Prevention, Screening and Health Maintenance
  48. [48]

    Duffy SA, Karvonen-Gutierrez CA, Ewing LA et al.. “Implementation of the Tobacco Tactics program in the Department of Veterans Affairs.” Journal of general internal medicine (2010). PMID: 20077145 ↗

    L2RCTCited in: Long-term and Definitive Management
  49. [49]

    Dhumal T, Kelly KM, Khadka S et al.. “Tobacco Cessation Interventions in Non-Respiratory Cancers: A Systematic Review With Meta-analysis of Randomized Controlled Trials.” Annals of behavioral medicine : a publication of the Society of Behavioral Medicine (2024). PMID: 38985846 ↗

    L1SR_MA_RCTCited in: Long-term and Definitive Management, Prevention, Screening and Health Maintenance
  50. [50]

    Leutwyler H, Hubbard E, Bussell T et al.. “A Pilot Randomized Controlled Trial of a Multicomponent Smoking Cessation Intervention for Adults with Serious Mental Illness.” Games for health journal (2024). PMID: 39587943 ↗

    L1RCTCited in: Long-term and Definitive Management, History and Evolution of Treatment, Prevention, Screening and Health Maintenance
  51. [51]

    Wang Y, Peng P, Wu Z et al.. “Boosting Smoking Cessation Intervention Utilization in Chinese Health Care Providers: A Randomized Controlled Trial of the "WeChat WeQuit" Medical Education Program.” Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco (2024). PMID: 39083005 ↗

    L1RCTCited in: Long-term and Definitive Management, History and Evolution of Treatment, Prognosis and Natural History
  52. [52]

    Hartmann-Boyce J, Lindson N. “Assessing and minimizing risk of bias in randomized controlled trials of tobacco cessation interventions: Guidance from the Cochrane Tobacco Addiction Group.” Addiction (Abingdon, England) (2023). PMID: 37132075 ↗

    L5RCTCited in: Long-term and Definitive Management
  53. [53]

    Olano-Espinosa E, Avila-Tomas JF, Minue-Lorenzo C et al.. “Effectiveness of a Conversational Chatbot (Dejal@bot) for the Adult Population to Quit Smoking: Pragmatic, Multicenter, Controlled, Randomized Clinical Trial in Primary Care.” JMIR mHealth and uHealth (2022). PMID: 35759328 ↗

    L1RCTCited in: Long-term and Definitive Management, History and Evolution of Treatment, Prognosis and Natural History
  54. [54]

    Fanshawe TR, Halliwell W, Lindson N et al.. “Tobacco cessation interventions for young people.” The Cochrane database of systematic reviews (2017). PMID: 29148565 ↗

    L1SR_OBSCited in: Long-term and Definitive Management, Prognosis and Natural History, Prevention, Screening and Health Maintenance
  55. [55]

    Maziak W, Jawad M, Jawad S et al.. “Interventions for waterpipe smoking cessation.” The Cochrane database of systematic reviews (2015). PMID: 26228266 ↗

    L1SR_OBSCited in: Long-term and Definitive Management, Prognosis and Natural History, Prevention, Screening and Health Maintenance
  56. [56]

    Asfar T, Livingstone-Banks J, Ward KD et al.. “Interventions for waterpipe smoking cessation.” The Cochrane database of systematic reviews (2023). PMID: 37286509 ↗

    L1SR_OBSCited in: Long-term and Definitive Management, Prognosis and Natural History, Prevention, Screening and Health Maintenance
  57. [57]

    Maziak W, Ward KD, Eissenberg T. “Interventions for waterpipe smoking cessation.” The Cochrane database of systematic reviews (2007). PMID: 17943865 ↗

    L1SR_OBSCited in: Long-term and Definitive Management, Prognosis and Natural History
  58. [58]

    Rasool S, Dobbie F, Khan Z et al.. “Process evaluation of a pragmatic feasibility trial on smokeless tobacco cessation intervention delivered in dental hospitals.” BMC public health (2024). PMID: 38755594 ↗

    L4TRIAL_NONRANDOMCited in: Long-term and Definitive Management
  59. [59]

    Pradhan PMS, Funnell MP, Sagtani RA et al.. “Effectiveness of tobacco cessation interventions delivered in clinical settings in South Asia: a systematic review and meta-analysis.” Global health action (2026). PMID: 42394572 ↗

    L1SR_OBSCited in: Long-term and Definitive Management, Prevention, Screening and Health Maintenance
  60. [60]

    . “Counseling and interventions to prevent tobacco use and tobacco-caused disease in adults and pregnant women: U.S. Preventive Services Task Force reaffirmation recommendation statement.” Annals of internal medicine (2009). PMID: 19380855 ↗

    L1GUIDELINECited in: History and Evolution of Treatment, Special Populations and Pregnancy, Prevention, Screening and Health Maintenance
  61. [61]

    . “A clinical practice guideline for treating tobacco use and dependence: A US Public Health Service report. The Tobacco Use and Dependence Clinical Practice Guideline Panel, Staff, and Consortium Representatives.” JAMA (2000). PMID: 10866874 ↗

    L1GUIDELINECited in: History and Evolution of Treatment
  62. [62]

    Lichtenstein E, Hollis JF, Severson HH et al.. “Tobacco cessation interventions in health care settings: rationale, model, outcomes.” Addictive behaviors (1996). PMID: 8904937 ↗

    L5RCTCited in: History and Evolution of Treatment
  63. [63]

    Rigotti NA, Tindle HA, Regan S et al.. “A Post-Discharge Smoking-Cessation Intervention for Hospital Patients: Helping Hand 2 Randomized Clinical Trial.” American journal of preventive medicine (2016). PMID: 27647060 ↗

    L1RCTCited in: History and Evolution of Treatment, Prognosis and Natural History, Prevention, Screening and Health Maintenance
  64. [64]

    Yuan NP, Castañeda H, Nichter M et al.. “Lay health influencers: how they tailor brief tobacco cessation interventions.” Health education & behavior : the official publication of the Society for Public Health Education (2011). PMID: 21986244 ↗

    L4RCTCited in: History and Evolution of Treatment
  65. [65]

    King BA, Dube SR, Babb SD et al.. “Patient-reported recall of smoking cessation interventions from a health professional.” Preventive medicine (2013). PMID: 23872172 ↗

    L4OTHERCited in: Generalist Reasoning under Diagnostic Uncertainty, Point-of-Care Scores & Referral Thresholds
  66. [66]

    Harrogate S, Barnes J, Thomas K et al.. “Peri-operative tobacco cessation interventions: a systematic review and meta-analysis.” Anaesthesia (2023). PMID: 37656151 ↗

    L1SR_OBSCited in: Complications
  67. [67]

    Harrogate SR, Barnes JD, Gupta S et al.. “Protocol for a systematic review and meta-analysis of tobacco-cessation interventions delivered perioperatively.” BMJ open (2023). PMID: 37714672 ↗

    L5SR_OBSCited in: Complications
  68. [68]

    Battalio SL, Pfammatter AF, Kershaw KN et al.. “Mobile Health Tobacco Cessation Interventions to Promote Health Equity: Current Perspectives.” Frontiers in digital health (2022). PMID: 35847415 ↗

    L5OTHERCited in: Complications
  69. [69]

    Hwong AR, Schmittdiel J, Schillinger D et al.. “Smoking cessation treatment for individuals with comorbid diabetes and serious mental illness in an integrated health care delivery system.” Addictive behaviors (2020). PMID: 33129613 ↗

    L3OTHERCited in: Complications
  70. [70]

    Veldheer S, Yingst J, Rogers AM et al.. “Completion rates in a preoperative surgical weight loss program by tobacco use status.” Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery (2017). PMID: 28392255 ↗

    L4OTHERCited in: Complications
  71. [71]

    Sarkar BK, West R, Arora M et al.. “Effectiveness of a brief community outreach tobacco cessation intervention in India: a cluster-randomised controlled trial (the BABEX Trial).” Thorax (2016). PMID: 27708113 ↗

    L1RCTCited in: Prognosis and Natural History
  72. [72]

    Jackson MA, Baker AL, McCarter KL et al.. “Interventions for pregnant women who use tobacco and other substances: a systematic review protocol.” BMJ open (2019). PMID: 31719091 ↗

    L5SR_OBSCited in: Special Populations and Pregnancy
  73. [73]

    Tong VT, Farr SL, Bombard J et al.. “Smoking Before and During Pregnancy Among Women Reporting Depression or Anxiety.” Obstetrics and gynecology (2016). PMID: 27500342 ↗

    L4OTHERCited in: Special Populations and Pregnancy
  74. [74]

    Dascăl MD, Meghea CI, Blaga OM. “A Cross-Section Study of Relationship Characteristics and Smoking Cessation During Pregnancy in a Sample of Romanian Pregnant Women.” Maternal and child health journal (2020). PMID: 32048171 ↗

    L4OTHERCited in: Special Populations and Pregnancy
  75. [75]

    Saygın Avşar T, Jackson L, McLeod H. “Potential for health economics to influence policies on tobacco use during pregnancy in low-income and middle-income countries: a qualitative case study.” BMJ open (2021). PMID: 34880008 ↗

    L5OTHERCited in: Special Populations and Pregnancy
  76. [76]

    Hyndman K, Thomas RE, Schira HR et al.. “The Effectiveness of Tobacco Dependence Education in Health Professional Students' Practice: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.” International journal of environmental research and public health (2019). PMID: 31661922 ↗

    L1SR_MA_RCTCited in: Prevention, Screening and Health Maintenance
  77. [77]

    Fernandez ME, Schlechter CR, Del Fiol G et al.. “QuitSMART Utah: an implementation study protocol for a cluster-randomized, multi-level Sequential Multiple Assignment Randomized Trial to increase Reach and Impact of tobacco cessation treatment in Community Health Centers.” Implementation science : IS (2020). PMID: 32000812 ↗

    L5TRIAL_NONRANDOMCited in: Prevention, Screening and Health Maintenance

Revision History

All updates applied to this page

Loading revisions…